Clinical Analysis of B-CLPD with Cytopemia as the Predominant Characteristic.
10.19746/j.cnki.issn.1009-2137.2019.03.032
- Author:
Rui LU
1
;
Zeng-Jun LI
2
;
Gang AN
1
;
Shu-Hua YI
1
;
Wei LIU
1
;
Ting-Yu WANG
1
;
Shu-Hui DENG
1
;
Wei-Wei SUI
1
;
De-Hui ZOU
1
;
Lu-Gui QIU
1
Author Information
1. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hpspital, Chinese Acadmy of Medical Sciences, Tianjin 30020, China.
2. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hpspital, Chinese Acadmy of Medical Sciences, Tianjin 30020, China,E-mail: zengjunli@163.com.cn.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Antigens, CD20;
Antineoplastic Combined Chemotherapy Protocols;
B-Lymphocytes;
Cyclophosphamide;
Humans;
Lymphoproliferative Disorders;
Middle Aged;
Retrospective Studies;
Rituximab
- From:
Journal of Experimental Hematology
2019;27(3):839-843
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics and therapeutic responte of patients with B-CLPD mainly manifested as cytopenia, so as to deeply understand this disease.
METHODS:The clinical data of 13 B-CLPD patients with hematocytopenia as main manifestation, and the absolute count of lymphocytes＜5×10/L, absence of hepatosplenic lymph-nodes and extramedullary invasion tin our department fron 2003 to 2018 were analyzed retrospectively. The clinical characteristics, therapeutic efficacy and adverse reactions of 3 patients were summarized.
RESULTS:The median age of patients was 59 (43-76) years old, the median of lymphocyte was 1.86 (0.69-4.8) ×10/L, the levels of LDH and β2-microglubulin were normal in most patients, the monolineage and multilencage hematopoietic failure of different degrees existed in most all patients. The lymphocyte ratio in patients was 18.5%-94.0%, CD20 was positive in all patients, and yet the CD5-positive and CD-negative existed in 7 and 6 cases respectively. There was no significant difference in ratio of lymphocyte invasion among different immunophemtype. The FISH detection showed that there were no high risk genetic types. 92.3% of patients received rituximab treatment, most of them received chemotherapy of rituximab combined with C0P/CHOP like regimen, only 2 patients received fludarabine for comparatively short course. The analysis indicated that 8 out of 13 patients showed a certain theropeutic efficacy, however the drug-related hematopoietic suppression occurred in both 2 patients treated with fludarabin.
CONCLUSIONS:The B-CLPD accompanied with hematocytopenia often displays bone marrow hypohematopoiesis of different degree and easily confuses with the congenital and acquired hemotopoietic faiture diseases. The rituximab treatment may be more appropreate for these patients, but for patients received chemotherapy containing fludarabin, the persistant hematopoietic failure must be especially watched out.
